Dr. Sandra Comer joins Sen-Jam Pharmaceuticals Scientific Advisory Board

Dr. Sandra Comer joins Sen-Jam Pharmaceuticals Scientific Advisory Board

Huntington, New York – October 23rd, 2017 – Sen-Jam Pharmaceutical is pleased to announce the addition of Dr. Sandra Comer to their Board of Scientific Advisors.

Dr. Sandra Comer is a Professor of Neurobiology in the Department of Psychiatry at the College of Physicians and Surgeons of Columbia University, and a Research Scientist VI at the New York State Psychiatric Institute. She received her BS at Vanderbilt University and her PhD at the University of Michigan for her research on the effects of opioids using preclinical models. Dr. Comer’s research focus at Columbia University has been on the clinical development and testing of novel approaches to the treatment of opioid use disorder, including the influence of sex differences and hormonal influences on responses to pain and opioid medications, the role of inflammation on opioid-mediated effects, and the ability of sustained-release medications to alter the subjective and reinforcing effects of opioids. She currently directs a very active laboratory to evaluate medications to treat OUD, as well combined opioid and alcohol use disorders. In addition, she is conducting a large, prospective, longitudinal study to evaluate ways to maximize the use and effectiveness of naloxone by opioid users to reverse opioid overdose. Dr. Comer also is evaluating the abuse liability of several commonly prescribed pain medications using laboratory models of drug self-administration in humans.

“Sandra brings a lifetime of experience to Opioid Use Disorder research and we look forward to working together to advance our science and commercialize a solution,” said Jim Iversen, Chief Executive Officer of Sen-Jam Pharmaceutical. “We are confident that she will add a great deal of value to our Scientific Advisory Board and Sen-Jam Pharmaceutical will benefit from her insights, judgment, and collaboration.”

Dr. Comer has served as a regular member of the National Institutes of Health Biobehavioral Regulation, Learning and Ethology (BRLE) study section and numerous ad hoc NIH grant review committees, and was a voting member of the Institutional Review Board of the New York State Psychiatric Institute and of the Faculty Council of the Faculty of Medicine. From 2015-2016, she served as President of the College on Problems of Drug Dependence, the longest standing scholarly society in the United States that is devoted to issues surrounding substance use disorders. She previously served as Program Chair and currently is serving as the Public Policy Officer for CPDD. Dr. Comer recently joined the Expert Advisory Panel on Drug Dependence for the World Health Organization. She is the author or co-author of more than 140 papers, chapters, and books dealing with several aspects of substance abuse.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical’s Mission is to Create Value by finding Novel Pharmaceutical Solutions for Large, Unmet Needs while Forging Global Sales, Distribution, and Licensing Agreements.